MedPath

A single blind randomised controlled trial comparing submandibular gland plus parotid sparing versus parotid sparing alone using volumetric modulated arc therapy in patients with head and neck cancer squamous cell carcinomas

Phase 3
Conditions
Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Registration Number
CTRI/2021/06/034033
Lead Sponsor
JIPMER
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients over 18 years of age

2. Patients with ECOG performance status 0 - 2

3. Patients of squamous cell carcinoma of the

head and neck planned for radical radiation with or without concurrent chemotherapy treated with volumetric modulated arc radiotherapy

Exclusion Criteria

1. Patients with previous history of radiotherapy to head and neck

2. Patients with T1N0M0 carcinoma glottis

3. Patients with carcinoma of the head and

neck in whom the submandibular glands are enclosed completely in the clinical target volume.

4. Tumour involvement of both the submandibular glands

5. Preâ??existing salivary gland disease

6. Previous or concurrent illness that would

compromise completion of treatment or

follow-up

7. Patient receiving prophylactic amifostine or pilocarpine

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the effect of sparing the submandibular gland on patient reported outcomes measured subjectively using xerostomia questionnaire XQ in head and neck cancer patients receiving Submandibular and Parotid sparing versus Parotid sparing using Volumetric modulated arc therapy VMATTimepoint: Pre radiation as baseline and at 3 months and at 6 months
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath